MX2023002093A - Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40). - Google Patents

Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40).

Info

Publication number
MX2023002093A
MX2023002093A MX2023002093A MX2023002093A MX2023002093A MX 2023002093 A MX2023002093 A MX 2023002093A MX 2023002093 A MX2023002093 A MX 2023002093A MX 2023002093 A MX2023002093 A MX 2023002093A MX 2023002093 A MX2023002093 A MX 2023002093A
Authority
MX
Mexico
Prior art keywords
antibody
treating
autoimmune disease
antagonistic
antigen binding
Prior art date
Application number
MX2023002093A
Other languages
English (en)
Spanish (es)
Inventor
Karen Price
Mary Struthers
Ying Ye
Urvi Aras
Nidhi Sharda
Ihab Girgis
Aberra Fura
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023002093A publication Critical patent/MX2023002093A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2023002093A 2020-08-25 2021-08-25 Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40). MX2023002093A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070209P 2020-08-25 2020-08-25
PCT/US2021/047610 WO2022046942A1 (en) 2020-08-25 2021-08-25 Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies

Publications (1)

Publication Number Publication Date
MX2023002093A true MX2023002093A (es) 2023-03-15

Family

ID=77693641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002093A MX2023002093A (es) 2020-08-25 2021-08-25 Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40).

Country Status (11)

Country Link
US (1) US20230331860A1 (https=)
EP (1) EP4204099A1 (https=)
JP (1) JP2023539736A (https=)
KR (1) KR20230054451A (https=)
CN (1) CN116322761A (https=)
AU (1) AU2021331087A1 (https=)
BR (1) BR112023002803A2 (https=)
CA (1) CA3190727A1 (https=)
IL (1) IL300765A (https=)
MX (1) MX2023002093A (https=)
WO (1) WO2022046942A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018361743A1 (en) * 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos

Also Published As

Publication number Publication date
AU2021331087A1 (en) 2023-04-20
CN116322761A (zh) 2023-06-23
JP2023539736A (ja) 2023-09-19
WO2022046942A1 (en) 2022-03-03
BR112023002803A2 (pt) 2023-03-14
IL300765A (en) 2023-04-01
CA3190727A1 (en) 2022-03-03
EP4204099A1 (en) 2023-07-05
US20230331860A1 (en) 2023-10-19
KR20230054451A (ko) 2023-04-24

Similar Documents

Publication Publication Date Title
Zhang et al. In vivo expansion of regulatory T cells with IL-2/IL-2 antibody complex protects against transient ischemic stroke
Rettew et al. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity
Bergmann et al. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma
Charpin et al. Immunohistochemical detection of laminin in 98 human breast carcinomas: a light and electron microscopic study
Meuer et al. Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes
Lauder et al. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
PH12022551650A1 (en) Anti-trem2 antibodies and methods of use thereof
Vondran et al. Impact of Basiliximab on regulatory T‐cells early after kidney transplantation: down‐regulation of CD25 by receptor modulation
MY204740A (en) Antagonistic cd40 monoclonal antibodies and uses thereof
Uppaluri et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody
PH12021552002A1 (en) Anti-trem2 antibodies and methods of use thereof
Jiang et al. Regulation of Laminin 1-Induced Pancreatic β-Cell Differentiation by α 6 Integrin and α-Dystroglycan
Vaillant et al. Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays?
Ribeiro et al. Intermediate expression of CCRL1 reveals novel subpopulations of medullary thymic epithelial cells that emerge in the postnatal thymus
WO2024105445A3 (en) Fcrn antagonist molecules and methods of use thereof
MX2023002093A (es) Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40).
Fukushima et al. TNFα-induced apoptosis and integrin switching in human extravillous trophoblast cell line
Magid-Bernstein et al. Human CD39+ Treg cells express Th17-associated surface markers and suppress IL-17 via a Stat3-dependent mechanism
Jimeno et al. Effect of VIP on the balance between cytokines and master regulators of activated helper T cells
Lader et al. Generation of human osteoclasts in stromal cell‐free and stromal cell‐rich cultures: Differences in osteoclast CD11c/CD18 integrin expression
MX2025003623A (es) Receptores modificados resistentes a anticuerpos para mejorar terapias basadas en celulas
Gunduz et al. T cell subpopulations and IL‐2R in vitiligo
Lepesant et al. Mouse thymic epithelial cell lines interact with and select a CD3lowCD4+ CD8+ thymocyte subset through an LFA-1-dependent adhesion-de-adhesion mechanism
Lim et al. China’s demographic outlook
Kreiss et al. The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells